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Abstract: The synthesis of two new organic compounds, diisobutyl- and diiso-
pentyl (S,S)-α1,α3-bis(cyclohexylmethyl-1,3-imidazolidinediacetate is reported 
herein. The one-pot procedure was realized by the addition of the reducing 
agent and carbonyl compound into a methanolic solution of the parent 
compounds (isobutyl and isopentyl esters of (S,S)-α,α′-(1,2-ethanediyldi-
imino)bis[cyclohexanepropanoic acid] in appropriate stoichiometric ratios. The 
compounds were fully characterized by infrared, ESI-MS, 1D (1H and 13C) and 
2D (COSY, HSQC and HMBC) NMR spectroscopy and elemental analysis. 
The spectral data confirmed the presence of the –CH2– group introduced 
between the nitrogen atoms of the ethylenediamine moiety, revealing a neutral 
form of the potential bidentate ligand. 
Keywords: cyclohexyl derivatives; ethylenediamine; amine ligands; potential 
drugs. 
INTRODUCTION 
The chemistry of anticancer agents generally refers to pure organic species1 
and metal containing compounds.2 After the promising discovery of cisplatin by 
Rosenberg in 1965,3 the subsequent intensive research in the field of bioinorg-
anic chemistry has resulted in the achievement of only slight progress.4 Now-
adays, the use of metal-based drugs is limited to cisplatin and its analogs, 
carboplatin and oxaliplatin.5 It is also noteworthy to mention the Ru(III) com-
plexes, NAMI-A (imidazolium trans-[tetrachloro(S-dimethyl sulfoxide)(1H-imi-
dazole)ruthenate(III)]) and KP1019 (indazolium [trans-tetrachlorobis(1H-inda-
zole)ruthenate(III)])6 that have both entered phase II of clinical trials. Therefore, 
an ideal drug in terms of being extremely toxic and simultaneously highly select-
ive is yet to be developed.  
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Although a major part of pharmaceutical industry is based on organic and 
biologically derived species, the synthetic routes still precede over natural pro-
ducts.7,8 The main reason is found in the opportunity to create a potential drug 
with the desired profile of biologic activity. Moreover, it is also possible to funct-
ionalize parent compounds by various structural modifications in order to utilize 
or expand their primary use. The structures of recently synthesized compounds 
with confirmed antitumor activity are given in Fig. S-1 of the Supplementary 
material to this paper. 
Based on the above-mentioned concept, the synthesis and cytotoxic studies 
of (S,S)-α,α′-(1,2-ethanediyldiimino)bis[cyclohexanepropanoic acid] and (S,S)- 
-α,α′-(1,3-propanediyldiimino)bis[cyclohexanepropanoic acid] joined with their 
corresponding esters and Pt(IV) and Ru(II) complexes were previously rep-
orted.9–13 The obtained results demonstrated strong antitumor potential and, in 
some cases, even better activity compared to that of the conventional cisplatin. 
The mechanism of cytotoxic activity for (S,S)-α,α′-(1,2-ethanediyldiimino)bis-
[cyclohexanepropanoate] was particularly investigated, revealing induced apop-
tosis associated with oxidative stress, mitochondrial depolarization and nuclear 
translocation of the apoptosis-inducing factor.14 
Since each study confirmed the positive influence of the variable length of 
the alkyl side chain on biological features (the longer the alkyl chain, the more 
active the compound),11 two derivatives with the bulky alkyl chain of (S,S)-α,α′- 
-(1,2-ethanediyldiimino)bis[cyclohexanepropanoic acid] were additionally syn-
thesized and fully characterized. Hence, the synthesis and characterization of 
diisobutyl- and diisopentyl (S,S)-α1,α3-bis(cyclohexylmethyl-1,3-imidazolidi-
nediacetate are reported herein. The structures of these two compounds are given 
in Fig. 1. 
Fig. 1. The structure of the syn-
thesized compounds, C1 and C2. 
EXPERIMENTAL 
Reagents and instruments 
The reagents and solvents were purchased from commercial suppliers and used without 
further purification. The precursor substances, isobutyl and isopentyl esters of (S,S)-α,α′-(1,2- 
-ethanediyldiimino)bis[cyclohexanepropanoate] were synthesized starting from (S)-2-amino- 
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-3-cyclohexylpropanoic acid hydrochloride purchased from Senn Chemicals (Dielsdorf, 
Switzerland). The preparation method was previously described and published.9,12  
Elemental analyses were performed on an Elemental Vario EL III microanalyzer. A 
Nicolet 6700 FT-IR spectrometer and the ATR technique were used for recording the infrared 
spectra. 1D (1H and 13C), 2D COSY (correlation spectroscopy) and 2D 1H–13C heteronuclear 
correlation spectra were recorded using a Bruker Avance III 500 spectrometer in CDCl3 with 
TMS as the reference. The mass spectra were obtained with an Orbitrap LTQ XL instrument 
(Thermo Scientific, Bremen, Germany) in methanol. 
Synthetic procedures 
Synthesis of the diisobutyl (S,S)-α1,α3-bis(cyclohexylmethyl-1,3-imidazolidinediacetate, 
C1. A suspension of the precursor, diisobutyl (S,S)-α,α′-(1,2-ethanediyldiimino)bis[cyclo-
hexanepropanoate] dihydrochloride (0.2 g, 0.36 mmol) in methanol (10 mL) was mixed and 
heated up to 40 °C for 20 min on a steam bath until the mixture was well homogenized. The 
methylation mixture was made by dissolving sodium triacetoxyborohydride (0.23 g, 1.08 
mmol) in methanol (10 mL) followed by the addition of 36 % aqueous formaldehyde (0.10 
mL, 3.61 mmol). The obtained methylation solution was poured dropwise into the previously 
made suspension. In order to adjust the pH value to 4–5, glacial acetic acid (0.25 mL) was 
slowly added to the reaction mixture. The next portion of the same volume was added after 2 
h and stirring was continued for the following 30 min. The whole reaction solution was 
washed out with diethyl ether (40 mL) followed by rinsing the ether extract with three equal 
portions of KOH solution (10 mL, 1 M) and a portion of brine (10 mL). The combined ether 
solutions were dried overnight using anhydrous K2CO3 and evaporated in vacuo to obtain a 
colorless oil.  
Synthesis of diisopentyl (S,S)-α1,α3-bis(cyclohexylmethyl-1,3-imidazolidinediacetate, C2. 
A suspension of the precursor, diisopentyl (S,S)- α,α′-(1,2-ethanediyldiimino)bis[cyclo-
hexanepropanoate] dihydrochloride (0.2 g, 0.34 mmol) in methanol (10 mL) was mixed and 
heated at 40 °C for 20 min on a steam bath until the mixture was well homogenized. The 
methylation mixture was made by dissolving sodium triacetoxyborohydride (0.22 g, 1.03 
mmol) in methanol (10 mL) followed by the addition of 36 % aqueous formaldehyde (0.09 
mL, 3.44 mmol). The further procedure involved the same treatment as for C1. 
The analytic and spectral data for C1 and C2 are given in the Supplementary material to 
this paper. 
RESULTS AND DISCUSSION 
Synthesis. The reductive methylation of diisobutyl- and diisopentyl esters of 
(S,S)-α,α′-(1,2-ethanediyldiimino)bis[cyclohexanepropanoic acid] was typi-
cal15,16 with slight modifications. The precursor ester was well homogenized in 
methanol. The mixture for methylation containing 36 % aqueous formaldehyde 
and sodium triacetoxyborohydride dissolved in methanol was slowly added to the 
ligand solution, which was then stirred for the following 2 h. The pH value was 
adjusted using glacial acetic acid. The obtained solution was treated with appro-
priate amounts of diethyl ether, 1 M KOH and brine. After drying the ether solu-
tions overnight, the compounds were obtained by evaporation in vacuo. The syn-
thesized compounds were soluble in common organic solvents (ethanol, dimethyl 
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sulfoxide, diethyl ether, acetone, dichloromethane and chloroform) but insoluble 
in water. 
Spectroscopic studies. The new compounds, C1 and C2, were characterized 
by mass spectrometry, infrared spectroscopy and one- (1H and 13C) and two- 
-dimensional homo and heteronuclear (1H/1H-COSY, HSQC and HMBC) NMR 
spectroscopy. Elemental analyses data were in a good agreement with the corres-
ponding composition of the synthesized compounds. 
The IR spectra of C1 and C2 showed strong bands at ≈1730 cm–1 assigned 
to the vibrations of the carbonyl group.17 Two strong bands originating from 
asymmetric C–H stretching vibrations were found at ≈2930 and ≈2850 cm–1. In 
addition, C–O stretching vibrations occurred around 1250 cm–1, while the C–N 
group exhibited a weak absorption at around 1165 cm–1. 
The proposed structures of compounds C1 and C2 were also confirmed by 
their mass spectra, which indicated to a [M+H]+ peak matched with the calcul-
ated molecular mass and proper isotope pattern. Furthermore, high intensities 
were also observed for peaks assigned to the [M–CH2+3H]+ fragment. 
The 1H-NMR spectrum of the products (given in the Supplementary material 
to this paper) indicated on the presence of cyclohexyl moiety arising in the area 
between 0.7–1.9 ppm with the exception of protons bonded to C5. Specifically, 
they appeared in a form of two separate sets of signals as their diastereotopic 
nature originates from the chiral C atom. Ethylenediamine protons were detected 
between 2.84 and 2.98 ppm in a form of two multiplets, as can be seen in Fig. 2, 
 
Fig. 2. 1H-NMR spectrum of compound C1 in the region 2.70–4.00 ppm 
recorded in CDCl3. 
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which shows the 1H-NMR spectrum of compound C1 in the region 2.70–4.00 
ppm. The multiplet located at ≈3.40 ppm was assigned to (ROOC)CH– protons. 
The presence of methylene bridged protons (–NCH2N–) was confirmed in the 
form of a singlet (3.63 ppm) that showed negative correlation with the carbon 
resonance at 69.55 ppm in the edited HSQC spectrum. The same signal was cor-
related to carbons at 48.23 (–NCH2CH2N–) and 62.05 ppm (–OOCCHN–) in the 
HMBC spectrum, additionally confirming the newly formed imidazolidine ring. 
The 13C-NMR spectra of C1 and C2, the HSQC NMR spectrum of C1 and the 
COSY spectrum of C2 are given in the Supplementary material to this paper.  
CONCLUSIONS 
The primary structure of the compounds derived from cyclohexyl edda deri-
vatives enables various structural modifications in ethylenediamine and alkyl 
chain moiety. In this sense, novel methylated forms of (S,S)-α,α′-(1,2-ethane-
diyldiimino)bis[cyclohexanepropanoic acid] which contained isobutyl and iso-
pentyl groups were synthesized. The main reason for extending the alkyl side 
chain we found in the fact that more bulky molecules show significantly better 
antitumor activity which is planned to be investigated. 
SUPPLEMENTARY MATERIAL 
Analytic and spectral data for C1 and C2 and Figs. S-1–S-7 are available electronically 
from http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
НОВИ МЕТИЛОВАНИ ЛИГАНДИ ЕТИЛЕНДИАМИНСКОГ ТИПА: СИНТЕЗА И 
КАРАКТЕРИЗАЦИЈА 
ЉИЉАНА Е. МИХАЈЛОВИЋ-ЛАЛИЋ, АЛЕКСАНДАР САВИЋ, ГАБРИЈЕЛА БРАЂАН, ТИБОР Ј. САБО 
и САЊА ГРГУРИЋ-ШИПКА 
Хемијски факултет Универзитета у Београду, Студентски трг 12–16, 11000 Београд 
Описана је синтеза два нова органска једињења, диизобутил- и диизопентил-(S,S)- 
-α1,α3-бис(циклохексилметил-1,3-имидазолидиндиацетат, која су добијена у реакцији 
изобутил и изопентил естара (S,S)-α,α′-(1,2-етандиилдиимино)бис[циклохексанпро-
панске киселине] са погодним метилујућим агенсом и формалдехидом у одговарајућем 
стехиометријском односу. Синтетисана једињења су потпуно окарактерисана инфрацр-
веном, ESI-MS, 1D (1H и 13C) and 2D (COSY, HSQC и HMBC) NMR спектроскопијом и 
елементалном анализом. Спектрални подаци су потврдили присуство –CH2– групе уве-
денe између два атома азота етилендиаминског дела, представљајући потенцијалне 
бидентатне лиганде. 
(Примљено 12. фебруара, ревидирано 11. априла, прихваћено 11. априла 2014) 
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